Publications
Publications
Show Results For
- All HBS Web
(373)
- Faculty Publications (45)
biotech
→
- June 2014 (Revised February 2017)
- Case
Kathy Giusti and the Multiple Myeloma Research Foundation
By: Richard G. Hamermesh, Joshua D. Margolis and Matthew G. Preble
What do you do when your rising professional career is cut short by an unexpected cancer diagnosis? Kathy Giusti shifted careers, built a new organization that transformed how cancer research is done, and now faces the challenge of sustaining the organization and its... View Details
Keywords: Philanthropy; Philanthropy Funding; Entrepreneurship; Health Care; Management Styles; Personalized Medicine; Health Care Outcomes; Cancer; Cancer Care In The U.S.; Personal Care; Leadership; Leading Change; Social Entrepreneurship; Philanthropy and Charitable Giving; Health Care and Treatment; Leadership Style; Management Style; Management Skills; Growth and Development Strategy; Business Strategy; Health; Health Industry; United States; Canada; Spain
- January 2014
- Supplement
Fred Khosravi and AccessClosure (C)
By: Richard Hamermesh and Lauren Barley
On September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the... View Details
- October 2013 (Revised January 2014)
- Supplement
Fred Khosravi and AccessClosure (B)
By: Richard G. Hamermesh and Lauren Barley
It was January 2013, and Fred Khosravi, chairman of the board of AccessClosure Inc., wondered what the new year had in store for him and AccessClosure, the company he founded in late 2002. Khosravi was cautiously optimistic—the Mountain View, California-based medical... View Details
- September 2013 (Revised November 2015)
- Case
Living Proof: Are We a Technology Company or a Beauty Company?
By: Willy Shih
Jon Flint came up with the idea of a science-based beauty company while talking with his hairdresser about the problems with typical hair and skin care products. Together with a small team that included Professor Robert Langer of MIT, he committed to assemble a team... View Details
Keywords: Hair Care; Personal Care; Science-based; R＆D; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Marketing; Marketing Strategy; Product Marketing; Product Positioning; Science-Based Business; Business Strategy; Commercialization; Corporate Strategy; Technology Platform; Expansion; Beauty and Cosmetics Industry; United States; Boston; Cambridge
- June 2013
- Article
Signals across Multiple Networks: How Venture Capital and Alliance Networks Affect Interorganizational Collaboration
By: Umit Ozmel, Jeffrey J. Reuer and Ranjay Gulati
In this paper, we examine the contingent effects of signals generated by different types of networks on new ventures' formation of future strategic alliances. We argue that the signaling value of a given tie in reducing adverse selection is more pronounced when another... View Details
- December 2012
- Teaching Note
Gene Patents (A) (TN)
By: Richard G. Hamermesh and Matthew Preble
This is the teaching note for case Gene Patents (A). In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our... View Details
- March 2011 (Revised February 2012)
- Case
Innovation and Growth at Actelion Ltd.
By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details
- March 2011
- Case
MorphoSys AG: The Evolution of a Biotechnology Business Model
By: Gary P. Pisano, Ryan Johnson and Carin-Isabel Knoop
In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this profitability not by developing and selling its own drugs, but by licensing access to its proprietary library of human antibodies. Recently,... View Details
- August 2010 (Revised January 2013)
- Case
Avi Kremer
By: Joshua D. Margolis and Mark Wetzel
If you were diagnosed with a terminal illness, how would you respond and what would you do with your remaining time? Avi Kremer contemplates four options for how to devote himself 18 months after being diagnosed with ALS. His experience thus far and the choices he... View Details
- October 2009 (Revised August 2014)
- Case
Tengion: Bringing Regenerative Medicine to Life
By: Elie Ofek and Polly Ross Ribatt
Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late... View Details
- December 2008 (Revised January 2011)
- Case
Arcadia Biosciences: Seeds of Change
By: Arthur A. Daemmrich, Forest L. Reinhardt and Mary Louise Shelman
Arcadia Biosciences is an entrepreneurial California agricultural biotech company seeking to earn carbon credits by modifying commodity crops for use in China and India. Eric Rey, Arcadia's CEO, faced a strategic inflection point in early September 2008. The company... View Details
- March 2007
- Teaching Note
Amgen Inc.'s Epogen-Commercializing the First Biotech Blockbuster Drug (TN)
Teaching note to 706454. View Details
- March 2007
- Teaching Note
Monsanto: Realizing Biotech Value in Brazil (TN)
By: David E. Bell and Mary L. Shelman
- January 2007
- Background Note
Note on Biotech Business Development
By: Richard G. Hamermesh and Robert F. Higgins
Describes the business development process in biotechnology companies. Topics covered include: participants in the licensing process and their interests, the major steps in the licensing process, the terms that are part of most agreements, and the most contentious... View Details
- December 2006 (Revised October 2007)
- Case
Monsanto: Realizing Biotech Value in Brazil
By: David E. Bell and Mary L. Shelman
In 2003, Monsanto's patented "Roundup Ready" technology was used illegally on 70-80% of the soybean area in southern Brazil. Under pressure from U.S. soybean growers, who were paying to license the technology, the firm implemented an innovative delivery-based... View Details
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details
- 2006
- Book
Science Business: The Promise, the Reality, and the Future of Biotech
By: Gary P. Pisano
Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details
- January 2006
- Case
Jack Strang at SequenceLabs
By: Mukti Khaire, John J. Gabarro and Lynda M. Applegate
How can entrepreneur manage his firm if things go wrong despite having a great idea, a solid team, and financial backing? Jack Strang founded a biotech firm with his friend Peter Evans, to develop molecular pathway-based "cures" for metabolic disorders. The idea was... View Details
- December 2005 (Revised May 2007)
- Case
Cynthia Fisher and the Rearing of ViaCell
By: Robert F. Higgins, Richard G. Hamermesh and Ingrid Vargas
Describes the start up of Viacord, a Boston-based medical services firm founded by Cynthia Fisher (HBS MBA) in 1993. Told from Fisher's perspective, the entrepreneur details the conceptualization and launch of the business and the many obstacles and expenses faced in... View Details
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details